Breast Cancer Clinical Trials

**SUSPENDED** ALLIANCE A011104  Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (Feig)

UCI 15-83  Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (Tromberg)

UCI 10-39  Predicting Pathological Response within the First Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured with Diffuse Optical Spectroscopic Imaging (DOSI) (Tromberg)

UCI 11-15  Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (Su)

UCI 11-21  Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (Su)

UCI 14-86  Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (Su)

UCI 16-23  Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (Anton-Culver)

---

**SCREENING / DIAGNOSTIC / EPIDEMIOLOGIC / INTERVENTIONAL**

**BREAST CANCER**

**CORRELATIVE / OBSERVATIONAL**

UCI 95-29  Measurement of Breast Tissue Optical Properties (Tromberg)

UCI 10-24  ATHENA Breast Health Network (Anton-Culver)

UCI 12-10  Development of a Quantitative Tissue Optical Index of Breast Density for Prediction of Hormone Therapy Response (O'Sullivan)

UCI 13-19  Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III BREAST CANCER (Darouij)

UCI 14-25  Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 14-62  Breast Tumor Oxygenation during Exercise (Tromberg)

UCI 14-81  Mi Salud, Mi Vida: A Self-Discovery Tool for Latina Breast Cancer Survivors (Sorkin)

**SUSPENDED** UCI 15-64  A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery (Lin)

**SUSPENDED** UCI 16-01  Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

**SUSPENDED** UCI 17-43  Blood Collection Protocol for Circulating Tumor Cells, Circulating Cancer Associated Fibroblasts and Tissue Factor in Breast Cancer Patients (Parajul)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**opening soon** 0318
Breast Cancer Therapeutic Clinical Trials

**Breast Cancer**

**Neo-Adjuvant**

- **UCI 14-67** A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

**Stage I-III**

- SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer (Mehta)
- SWOG S1418 Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (Mehta)
- ALLIANCE A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Mehta)
- NSABP B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Darouei)

**Adjuvant**

**HER2-High Risk**

**Adjuvant**

**Hormone+ High Risk**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**opening soon**
**UCI 17-90** A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (Ou)

**UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

**UCI 16-74** A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)

**ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (Bota)

**NRG BR002** A Phase II/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (Daroui)

**UCI 17-79** Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (Parajuli)

**UCI 18-06** A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (Parajuli)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu